Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Mabs
|
September 6, 2018
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
Douglas D Leipold, Isabel Figueroa, Shabkhaiz Masih, et al.
ACS Medicinal Chemistry Letters
|
October 24, 2017
Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors
Leanna R Staben, Shang-Fan Yu, Jinhua Chen, et al.
Bioconjugate Chemistry
|
June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates
Jack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.
Bioconjugate Chemistry
|
February 27, 2018
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
Dian Su, Katherine R Kozak, Jack Sadowsky, et al.
Journal of Medicinal Chemistry
|
September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering
Thomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Leukemia
|
January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Molecular Cancer Therapeutics
|
February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers
Thomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.
Nature Biotechnology
|
January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen, Keyang Xu, Luna Liu, et al.
Chemical Science
|
April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
Neelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Bioconjugate Chemistry
|
April 11, 2019
Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
Dian Su, Jinhua Chen, Ely Cosino, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Mabs
|
September 6, 2018
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
Douglas D Leipold, Isabel Figueroa, Shabkhaiz Masih, et al.
ACS Medicinal Chemistry Letters
|
October 24, 2017
Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors
Leanna R Staben, Shang-Fan Yu, Jinhua Chen, et al.
Bioconjugate Chemistry
|
June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates
Jack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.
Bioconjugate Chemistry
|
February 27, 2018
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
Dian Su, Katherine R Kozak, Jack Sadowsky, et al.
Journal of Medicinal Chemistry
|
September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering
Thomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Leukemia
|
January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Molecular Cancer Therapeutics
|
February 23, 2017
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers
Thomas H Pillow, Melissa Schutten, Shang-Fan Yu, et al.
Nature Biotechnology
|
January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen, Keyang Xu, Luna Liu, et al.
Chemical Science
|
April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
Neelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Bioconjugate Chemistry
|
April 11, 2019
Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
Dian Su, Jinhua Chen, Ely Cosino, et al.
Page
of 6